Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19022335 | 0.68 | SIGMAR1 (0.47) | SIGMAR1CYP3A4CYP2D6TSHRTACR1 | |
| SCHEMBL23394854 | 0.67 | TACR1 (0.33) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL8577221 | 0.66 | RAB9A (0.50) | SIGMAR1TSHRNPC1 | |
| SCHEMBL13783262 | 0.66 | POLB (0.54) | SIGMAR1TSHRKCNH2ALDH1A1 | |
| SCHEMBL20328750 | 0.65 | TSHR (0.50) | SIGMAR1CYP3A4CYP2D6TSHRKCNH2 | |
| SCHEMBL25263718 | 0.65 | SIGMAR1 (0.48) | SIGMAR1TSHRKCNH2ALDH1A1KDM4E | |
| SCHEMBL20579315 | 0.65 | TACR1 (0.32) | TACR1SLC6A4KCNH2 | |
| SCHEMBL20579245 | 0.65 | GRN (0.35) | CYP3A4TACR1SLC6A4KCNH2NPC1 | |
| SCHEMBL20249190 | 0.64 | CA12 (0.58) | SIGMAR1CYP3A4CYP2D6KCNH2NPC1 | |
| SCHEMBL21348742 | 0.64 | SIGMAR1 (0.45) | SIGMAR1TSHRNPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634961-B1 | (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2021-05-26 | — | — | EP | disclosed |
| US-10364245-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364245-B2 | Kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | SIGMAR1 3052/4885CYP3A4 1986/4885CYP2D6 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.